Stephen Slocum
Director - Drug Development, Project Lead LigaChem Biosciences
Stephen Slocum is Director of Drug Development at LigaChem Biosciences, where he leads development of preclinical and early clinical programs for next generation ADCs. He brings expertise in PK/PD, toxicology, and translational strategy, guiding programs from discovery through first in human studies. Previously, he has served as a project lead coordinating cross functional development efforts across oncology pipelines.
Seminars
Tuesday 13th October 2026
LCB02A: Showcasing a CLDN18.2-Targeting ADC Utilizing LigaChem Biosciences’ Site-Specific Bioconjugation & Linker Technology
11:30 am
- Utilizing the site specific ConjuAll platform to build a discrete DAR ADC with circulation stable bioconjugation in combination with a proprietarty beta-glucuronidase linker
- Exploring how ConjuAll platform design corresponds to LCB02A’s excellent preclinical therapeutic index
- Building out a clinical strategy to rapidly generate LCB02A clinical proof of concept
Wednesday 14th October 2026
Reviewing Case Studies to Understand How ADC Design Influences Early-Stage Clinical Outcomes
11:00 am
- Evaluating opportunities for ADCs with novel design to deliver differentiated clinical outcomes
- Reviewing early-stage clinical results from LCB14 to understand the impact of bioconjugation and linker within the HER2 targeting ADC space
- Delving into the early clinical profile of LCB71, a pro-PBD bearing ROR1 targeting ADC, demonstrating differentiated clinical safety and efficacy
